TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2009

Randomized phase II trial of docetaxel plus cetuximab or docetaxel plus bortezomib in patients with advanced non-small-cell lung cancer and a performance status of 2: CALGB 30402.

Rogerio Lilenbaum et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.